|
Treatment facility volume and survival in patients with advanced prostate cancer. |
|
|
No Relationships to Disclose |
|
|
Research Funding - Pfizer (Inst); Pfizer (Inst); Pfizer (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - EMD Serono; Horizon Pharma; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Horizon Pharma (Inst); Pfizer (Inst) |
Other Relationship - Association of Community Cancer Centers (ACCC) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Genentech/Roche; Johnson & Johnson; Pfizer |
Speakers' Bureau - Janssen Oncology |
Research Funding - Novartis |
|
|
Employment - Visible Health |
Leadership - Visible Health |
Stock and Other Ownership Interests - Visible Health |
Consulting or Advisory Role - Novartis |
Travel, Accommodations, Expenses - Genomic Health |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Exelixis; Pfizer; Seattle Genetics/Astellas |
Research Funding - Astellas Pharma (Inst); Calithera Biosciences (Inst); Genentech (Inst); Merck (Inst) |